DURECT Corporation (NASDAQ: DRRX) announced today positive results from a 60 patient Phase IIb clinical trial of POSIDUR, a proprietary ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE